{"transactions":[{"id":802040,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-23T22:48:25.000Z","date":"2026-04-21","kind":"purchase","planned":false,"acquired":true,"shares":1126126,"price":4.44,"value":4999999.44,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were purchased in an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is filed by OrbiMed Advisors, GP VI, OrbiMed Capital and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VI have designated a representative, David Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report on Form 4 shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1126126,"source":{"system":"sec-edgar","filing":"0000947871-26-000461","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000461/ownership.xml","form_type":"4"}},{"id":802039,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-23T22:48:25.000Z","date":"2026-04-21","kind":"purchase","planned":false,"acquired":true,"shares":1689189,"price":4.44,"value":7499999.16,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were purchased in an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is filed by OrbiMed Advisors, GP VI, OrbiMed Capital and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VI have designated a representative, David Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report on Form 4 shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":11808945,"source":{"system":"sec-edgar","filing":"0000947871-26-000461","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000461/ownership.xml","form_type":"4"}},{"id":1421097,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-28T20:26:15.000Z","date":"2024-08-26","kind":"sale","planned":false,"acquired":false,"shares":83695,"price":13,"value":1088035.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $12.59 to a high of $13.35 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors LLC (\"OrbiMed Advisors\"). OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of OrbiMed Advisors, GP VI, and OrbiMed Capital disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VI have designated a representative, Peter Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-24-000728","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000728/ownership.xml","form_type":"4"}},{"id":1424541,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-23T22:38:24.000Z","date":"2024-08-23","kind":"sale","planned":false,"acquired":false,"shares":69500,"price":13.03,"value":905585.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $12.80 to a high of $13.20 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors LLC (\"OrbiMed Advisors\"). OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, GP VI, and OrbiMed Capital disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VI have designated a representative, Peter Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":83695,"source":{"system":"sec-edgar","filing":"0000947871-24-000720","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000720/ownership.xml","form_type":"4"}},{"id":1424540,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-23T22:38:24.000Z","date":"2024-08-22","kind":"sale","planned":false,"acquired":false,"shares":391482,"price":12.94,"value":5065777.08,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $12.765 to a high of $13.475 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors LLC (\"OrbiMed Advisors\"). OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, GP VI, and OrbiMed Capital disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VI have designated a representative, Peter Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":153195,"source":{"system":"sec-edgar","filing":"0000947871-24-000720","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000720/ownership.xml","form_type":"4"}},{"id":1424539,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-23T22:38:24.000Z","date":"2024-08-21","kind":"sale","planned":false,"acquired":false,"shares":13300,"price":14.61,"value":194313.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $14.605 to a high of $14.615 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors LLC (\"OrbiMed Advisors\"). OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, GP VI, and OrbiMed Capital disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VI have designated a representative, Peter Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":544677,"source":{"system":"sec-edgar","filing":"0000947871-24-000720","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000720/ownership.xml","form_type":"4"}},{"id":1424538,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-23T22:38:24.000Z","date":"2024-08-21","kind":"sale","planned":false,"acquired":false,"shares":394400,"price":13.52,"value":5332288.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $13.30 to a high of $13.925 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors LLC (\"OrbiMed Advisors\"). OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, GP VI, and OrbiMed Capital disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VI have designated a representative, Peter Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":557977,"source":{"system":"sec-edgar","filing":"0000947871-24-000720","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000720/ownership.xml","form_type":"4"}},{"id":1547118,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-05T20:33:30.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":450000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for (i) $2.5879 in cash per share (the \"Cash Amount\"), plus (ii) one non-transferable contingent value right (\"CVR\") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-24-000353","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000353/ownership.xml","form_type":"4"}},{"id":1547117,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-05T20:33:30.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":84599,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for (i) $2.5879 in cash per share (the \"Cash Amount\"), plus (ii) one non-transferable contingent value right (\"CVR\") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"OrbiMed Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-24-000353","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000353/ownership.xml","form_type":"4"}},{"id":1547116,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-05T20:33:30.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1368338,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for (i) $2.5879 in cash per share (the \"Cash Amount\"), plus (ii) one non-transferable contingent value right (\"CVR\") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-24-000353","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000353/ownership.xml","form_type":"4"}},{"id":1547115,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-05T20:33:30.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4738453,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for (i) $2.5879 in cash per share (the \"Cash Amount\"), plus (ii) one non-transferable contingent value right (\"CVR\") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-24-000353","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000353/ownership.xml","form_type":"4"}},{"id":1547114,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-05T20:33:30.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1368339,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for (i) $2.5879 in cash per share (the \"Cash Amount\"), plus (ii) one non-transferable contingent value right (\"CVR\") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the advisory company of OAP IV. By virtue of such relationships, Asia GP, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the securities held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-24-000353","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000353/ownership.xml","form_type":"4"}},{"id":1792181,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-31T21:26:17.000Z","date":"2023-08-29","kind":"purchase","planned":false,"acquired":true,"shares":500000,"price":6.2,"value":3100000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of the Issuer's common stock were purchased in a private transaction pursuant to the terms of a Stock Purchase Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of OrbiMed Advisors, GP VI, and OrbiMed Capital disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VI have designated a representative, Peter Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":8019187,"source":{"system":"sec-edgar","filing":"0000947871-23-000915","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000915/ownership.xml","form_type":"4"}},{"id":1880128,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T21:09:29.000Z","date":"2023-05-22","kind":"purchase","planned":false,"acquired":true,"shares":869565,"price":5.75,"value":4999998.75,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were purchased from the Issuer in an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, GP VI, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VI have designated a representative, David Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":10119756,"source":{"system":"sec-edgar","filing":"0000947871-23-000628","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000628/ownership.xml","form_type":"4"}},{"id":1901251,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-08T21:22:18.000Z","date":"2023-05-05","kind":"purchase","planned":false,"acquired":true,"shares":490511,"price":2.82,"value":1383241.02,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.80 to a high of $2.89 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1368338,"source":{"system":"sec-edgar","filing":"0000947871-23-000541","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000541/ownership.xml","form_type":"4"}},{"id":1901250,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-08T21:22:18.000Z","date":"2023-05-05","kind":"purchase","planned":false,"acquired":true,"shares":490512,"price":2.82,"value":1383243.84,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.80 to a high of $2.89 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the advisory company of OAP IV. By virtue of such relationships, Asia GP, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the securities held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1368339,"source":{"system":"sec-edgar","filing":"0000947871-23-000541","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000541/ownership.xml","form_type":"4"}},{"id":1901249,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-08T21:22:18.000Z","date":"2023-05-04","kind":"purchase","planned":false,"acquired":true,"shares":83459,"price":2.75,"value":229512.25,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.75 to a high of $2.86 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":877827,"source":{"system":"sec-edgar","filing":"0000947871-23-000541","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000541/ownership.xml","form_type":"4"}},{"id":1901248,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-08T21:22:18.000Z","date":"2023-05-04","kind":"purchase","planned":false,"acquired":true,"shares":312991,"price":2.75,"value":860725.25,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.75 to a high of $2.86 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4738453,"source":{"system":"sec-edgar","filing":"0000947871-23-000541","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000541/ownership.xml","form_type":"4"}},{"id":1901247,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-08T21:22:18.000Z","date":"2023-05-04","kind":"purchase","planned":false,"acquired":true,"shares":83459,"price":2.75,"value":229512.25,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.75 to a high of $2.86 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the advisory company of OAP IV. By virtue of such relationships, Asia GP, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the securities held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":877827,"source":{"system":"sec-edgar","filing":"0000947871-23-000541","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000541/ownership.xml","form_type":"4"}},{"id":1908956,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T01:34:38.000Z","date":"2023-05-02","kind":"purchase","planned":false,"acquired":true,"shares":58826,"price":2.67,"value":157065.42,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.57 to a high of $2.82 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":794368,"source":{"system":"sec-edgar","filing":"0000947871-23-000515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000515/ownership.xml","form_type":"4"}},{"id":1908955,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T01:34:38.000Z","date":"2023-05-02","kind":"purchase","planned":false,"acquired":true,"shares":220610,"price":2.67,"value":589028.7,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.57 to a high of $2.82 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4425462,"source":{"system":"sec-edgar","filing":"0000947871-23-000515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000515/ownership.xml","form_type":"4"}},{"id":1908954,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T01:34:38.000Z","date":"2023-05-02","kind":"purchase","planned":false,"acquired":true,"shares":58826,"price":2.67,"value":157065.42,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.57 to a high of $2.82 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the advisory company of OAP IV. By virtue of such relationships, Asia GP, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the securities held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":794368,"source":{"system":"sec-edgar","filing":"0000947871-23-000515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000515/ownership.xml","form_type":"4"}},{"id":1908953,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T01:34:38.000Z","date":"2023-05-01","kind":"purchase","planned":false,"acquired":true,"shares":124545,"price":2.62,"value":326307.9,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.59 to a high of $2.64 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":735542,"source":{"system":"sec-edgar","filing":"0000947871-23-000515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000515/ownership.xml","form_type":"4"}},{"id":1908952,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T01:34:38.000Z","date":"2023-05-01","kind":"purchase","planned":false,"acquired":true,"shares":467068,"price":2.62,"value":1223718.16,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.59 to a high of $2.64 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4204852,"source":{"system":"sec-edgar","filing":"0000947871-23-000515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000515/ownership.xml","form_type":"4"}},{"id":1908951,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T01:34:38.000Z","date":"2023-05-01","kind":"purchase","planned":false,"acquired":true,"shares":124544,"price":2.62,"value":326305.28,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.59 to a high of $2.64 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the advisory company of OAP IV. By virtue of such relationships, Asia GP, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the securities held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":735542,"source":{"system":"sec-edgar","filing":"0000947871-23-000515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000515/ownership.xml","form_type":"4"}},{"id":1908950,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T01:34:38.000Z","date":"2023-04-28","kind":"purchase","planned":false,"acquired":true,"shares":60997,"price":2.55,"value":155542.35,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":610997,"source":{"system":"sec-edgar","filing":"0000947871-23-000515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000515/ownership.xml","form_type":"4"}},{"id":1908949,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T01:34:38.000Z","date":"2023-04-28","kind":"purchase","planned":false,"acquired":true,"shares":228754,"price":2.55,"value":583322.7,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3737784,"source":{"system":"sec-edgar","filing":"0000947871-23-000515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000515/ownership.xml","form_type":"4"}},{"id":1908948,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T01:34:38.000Z","date":"2023-04-28","kind":"purchase","planned":false,"acquired":true,"shares":60998,"price":2.55,"value":155544.9,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the advisory company of OAP IV. By virtue of such relationships, Asia GP, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the securities held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":610998,"source":{"system":"sec-edgar","filing":"0000947871-23-000515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000515/ownership.xml","form_type":"4"}},{"id":1996587,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-23T19:16:09.000Z","date":"2023-02-17","kind":"grant","acquired":true,"shares":550000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was previously reported on the Form 3 jointly filed by OrbiMed Capital GP VIII LLC (\"GP VIII\"), OrbiMed Asia GP IV, L.P. (\"Asia GP\"), and OrbiMed Advisors IV Limited (\"Advisors IV\") on February 23, 2023 and is reported on this Form 4 as a transaction by OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares of the Issuer's common stock were acquired from the Issuer in exchange for Series A preferred shares of Kinnjiu Biopharma Inc. pursuant to a transaction approved by an independent committee of the Issuer's board of directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). Asia GP is the general partner of OAP IV and Advisors IV is the general partner of Asia GP. OrbiMed Advisors is the advisory company of OAP IV. By virtue of such relationships, Asia GP, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the securities held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":550000,"source":{"system":"sec-edgar","filing":"0000947871-23-000220","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000220/ownership.xml","form_type":"4"}},{"id":1996586,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-23T19:16:09.000Z","date":"2023-02-17","kind":"grant","acquired":true,"shares":550000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was previously reported on the Form 3 jointly filed by OrbiMed Capital GP VIII LLC (\"GP VIII\"), OrbiMed Asia GP IV, L.P. (\"Asia GP\"), and OrbiMed Advisors IV Limited (\"Advisors IV\") on February 23, 2023 and is reported on this Form 4 as a transaction by OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares of the Issuer's common stock were acquired from the Issuer in exchange for Series A preferred shares of Kinnjiu Biopharma Inc. pursuant to a transaction approved by an independent committee of the Issuer's board of directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). GP VIII is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":550000,"source":{"system":"sec-edgar","filing":"0000947871-23-000220","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000220/ownership.xml","form_type":"4"}},{"id":2217707,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":2,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2022-07-01T20:50:05.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":170437,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc (\"GSK\") and a subsidiary of GSK (the \"Merger\"), the Company's outstanding warrants will be treated in accordance with their respective terms. At the effective time of the Merger, any of the Company's outstanding Series A warrants will be cancelled and represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants) which is calculated under the terms of the Series A warrants to be $45.98 per share of our common stock subject to the Series A warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2019-11-13","expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":170437},"source":{"system":"sec-edgar","filing":"0001209191-22-040288","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919122040288/doc4.xml","form_type":"4"}},{"id":2217706,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":2,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2022-07-01T20:50:05.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":170437,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc (\"GSK\") and a subsidiary of GSK (the \"Merger\"), the Company's outstanding warrants will be treated in accordance with their respective terms. At the effective time of the Merger, any of the Company's outstanding Series A warrants will be cancelled and represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants) which is calculated under the terms of the Series A warrants to be $45.98 per share of our common stock subject to the Series A warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2019-11-13","expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":170437},"source":{"system":"sec-edgar","filing":"0001209191-22-040288","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919122040288/doc4.xml","form_type":"4"}},{"id":2217705,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":2,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2022-07-01T20:50:05.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":1136250,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc (\"GSK\") and a subsidiary of GSK (the \"Merger\"), the Company's outstanding warrants will be treated in accordance with their respective terms. At the effective time of the Merger, any of the Company's outstanding Series A warrants will be cancelled and represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants) which is calculated under the terms of the Series A warrants to be $45.98 per share of our common stock subject to the Series A warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2019-11-13","expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":1136250},"source":{"system":"sec-edgar","filing":"0001209191-22-040288","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919122040288/doc4.xml","form_type":"4"}},{"id":2217704,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":2,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-01T20:50:05.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":226704,"price":55,"value":12468720.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-040288","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919122040288/doc4.xml","form_type":"4"}},{"id":2217703,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":2,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-01T20:50:05.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":226704,"price":55,"value":12468720.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-040288","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919122040288/doc4.xml","form_type":"4"}},{"id":2217702,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":2,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-01T20:50:05.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":1511362,"price":55,"value":83124910.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-040288","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919122040288/doc4.xml","form_type":"4"}},{"id":2220432,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":2,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":3,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-28T20:29:40.000Z","date":"2022-06-24","kind":"sale","acquired":false,"shares":35944,"price":21.31,"value":765966.64,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were sold in multiple transactions at prices ranging from $21.17 to $21.75. The price reported reflects the weighted average sale price. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Shares are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is filed by OrbiMed Advisors, OrbiMed GP VII and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":415142,"source":{"system":"sec-edgar","filing":"0000947871-22-000727","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000727/ownership.xml","form_type":"4"}},{"id":2220431,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":2,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":3,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-28T20:29:40.000Z","date":"2022-06-24","kind":"sale","acquired":false,"shares":306027,"price":21.31,"value":6521435.37,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were sold in multiple transactions at prices ranging from $21.17 to $21.75. The price reported reflects the weighted average sale price. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Shares are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"OrbiMed GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of OrbiMed GP VII. OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is filed by OrbiMed Advisors, OrbiMed GP VII and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3534537,"source":{"system":"sec-edgar","filing":"0000947871-22-000727","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000727/ownership.xml","form_type":"4"}},{"id":2300562,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":2,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":3,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-08T22:06:23.000Z","date":"2022-04-08","kind":"sale","acquired":false,"shares":102800,"price":20.71,"value":2128988.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares of the Issuer's common stock (\"Shares\") were sold in a block at a price of $20.71"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Shares are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is filed by OrbiMed Advisors, OrbiMed GP VII, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":451086,"source":{"system":"sec-edgar","filing":"0000947871-22-000450","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000450/ownership.xml","form_type":"4"}},{"id":2300561,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":2,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":3,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-08T22:06:23.000Z","date":"2022-04-08","kind":"sale","acquired":false,"shares":97200,"price":20.71,"value":2013012.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares of the Issuer's common stock (\"Shares\") were sold in a block at a price of $20.71"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Shares are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"OrbiMed GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of OrbiMed GP VII. OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is filed by OrbiMed Advisors, OrbiMed GP VII, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3840564,"source":{"system":"sec-edgar","filing":"0000947871-22-000450","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000450/ownership.xml","form_type":"4"}},{"id":2300560,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":2,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":3,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-08T22:06:23.000Z","date":"2022-04-07","kind":"sale","acquired":false,"shares":177196,"price":20.66,"value":3660869.36,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares of the Issuer's common stock (\"Shares\") were sold in a block at a price of $20.66."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Shares are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is filed by OrbiMed Advisors, OrbiMed GP VII, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":553886,"source":{"system":"sec-edgar","filing":"0000947871-22-000450","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000450/ownership.xml","form_type":"4"}},{"id":2300559,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":2,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":3,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-08T22:06:23.000Z","date":"2022-04-07","kind":"sale","acquired":false,"shares":167800,"price":20.66,"value":3466748.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares of the Issuer's common stock (\"Shares\") were sold in a block at a price of $20.66."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Shares are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"OrbiMed GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of OrbiMed GP VII. OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is filed by OrbiMed Advisors, OrbiMed GP VII, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3937764,"source":{"system":"sec-edgar","filing":"0000947871-22-000450","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000450/ownership.xml","form_type":"4"}},{"id":2300558,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":2,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":3,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-08T22:06:23.000Z","date":"2022-04-06","kind":"sale","acquired":false,"shares":171204,"price":20.69,"value":3542210.76,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were sold in a block at a price of $20.69."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Shares are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is filed by OrbiMed Advisors, OrbiMed GP VII, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":731082,"source":{"system":"sec-edgar","filing":"0000947871-22-000450","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000450/ownership.xml","form_type":"4"}},{"id":2300557,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":2,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":3,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-08T22:06:23.000Z","date":"2022-04-06","kind":"sale","acquired":false,"shares":162000,"price":20.69,"value":3351780.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were sold in a block at a price of $20.69."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Shares are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"OrbiMed GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of OrbiMed GP VII. OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is filed by OrbiMed Advisors, OrbiMed GP VII, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4105564,"source":{"system":"sec-edgar","filing":"0000947871-22-000450","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000450/ownership.xml","form_type":"4"}},{"id":2313353,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-31T21:30:50.000Z","date":"2022-03-31","kind":"sale","acquired":false,"shares":34500,"price":21.17,"value":730365.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares of the Issuer's common stock (\"Shares\") were sold in a block at a price of $21.17."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of the Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"This report on Form 4 is jointly filed by OrbiMed Advisors LLC, GP V, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-22-000429","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000429/ownership.xml","form_type":"4"}},{"id":2313352,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-31T21:30:50.000Z","date":"2022-03-30","kind":"sale","acquired":false,"shares":75000,"price":22.39,"value":1679250.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares of the Issuer's common stock (\"Shares\") were sold in a block at a price of $22.39."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of the Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"This report on Form 4 is jointly filed by OrbiMed Advisors LLC, GP V, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":34500,"source":{"system":"sec-edgar","filing":"0000947871-22-000429","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000429/ownership.xml","form_type":"4"}},{"id":2313351,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-31T21:30:50.000Z","date":"2022-03-29","kind":"sale","acquired":false,"shares":365000,"price":21.52,"value":7854800.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were sold in a block at a price of $21.52."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of the Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"This report on Form 4 is jointly filed by OrbiMed Advisors LLC, GP V, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":109500,"source":{"system":"sec-edgar","filing":"0000947871-22-000429","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000429/ownership.xml","form_type":"4"}},{"id":2395051,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-16T02:42:44.000Z","date":"2022-02-15","kind":"purchase","acquired":true,"shares":9000,"price":9.96,"value":89640.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were purchased in a block order at the price stated in Table I."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationship, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Gordon, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose"}],"balance_after":3509030,"source":{"system":"sec-edgar","filing":"0000947871-22-000254","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000254/ownership.xml","form_type":"4"}},{"id":2395050,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-16T02:42:44.000Z","date":"2022-02-14","kind":"purchase","acquired":true,"shares":10000,"price":9.89,"value":98900.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were purchased in a block order at the price stated in Table I."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationship, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Gordon, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose"}],"balance_after":3500030,"source":{"system":"sec-edgar","filing":"0000947871-22-000254","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000254/ownership.xml","form_type":"4"}},{"id":2395049,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-16T02:42:44.000Z","date":"2022-02-14","kind":"purchase","acquired":true,"shares":20700,"price":9.98,"value":206586.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were purchased in a block order at the price stated in Table I."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationship, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Gordon, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose"}],"balance_after":3490030,"source":{"system":"sec-edgar","filing":"0000947871-22-000254","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000254/ownership.xml","form_type":"4"}},{"id":2395048,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-16T02:42:44.000Z","date":"2022-02-11","kind":"purchase","acquired":true,"shares":156000,"price":10.22,"value":1594320.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were purchased in a block order at the price stated in Table I."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationship, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Gordon, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose"}],"balance_after":3469330,"source":{"system":"sec-edgar","filing":"0000947871-22-000254","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000254/ownership.xml","form_type":"4"}},{"id":2422912,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants","published_at":"2022-01-29T02:22:18.000Z","date":"2022-01-26","kind":"other","acquired":false,"shares":56244,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"Consists of Series B warrants previously held by Genesis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The expiration date of the warrants is the date on the seventy-fifth (75th) day anniversary of the announcement by Issuer, via publicly disseminated press release or SEC filing, of the top-line data results from MOMENTUM, its Phase 3 clinical trial of momelotinib for patients with myelofibrosis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":56244},"source":{"system":"sec-edgar","filing":"0001209191-22-005511","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919122005511/doc4.xml","form_type":"4"}},{"id":2422911,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants","published_at":"2022-01-29T02:22:18.000Z","date":"2022-01-26","kind":"other","acquired":false,"shares":56244,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"Consists of Series B warrants previously held by OPM."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The expiration date of the warrants is the date on the seventy-fifth (75th) day anniversary of the announcement by Issuer, via publicly disseminated press release or SEC filing, of the top-line data results from MOMENTUM, its Phase 3 clinical trial of momelotinib for patients with myelofibrosis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":56244},"source":{"system":"sec-edgar","filing":"0001209191-22-005511","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919122005511/doc4.xml","form_type":"4"}},{"id":2422910,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants","published_at":"2022-01-29T02:22:18.000Z","date":"2022-01-26","kind":"other","acquired":false,"shares":374962,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Consists of Series B warrants previously held by OPI VII."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The expiration date of the warrants is the date on the seventy-fifth (75th) day anniversary of the announcement by Issuer, via publicly disseminated press release or SEC filing, of the top-line data results from MOMENTUM, its Phase 3 clinical trial of momelotinib for patients with myelofibrosis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":374962},"source":{"system":"sec-edgar","filing":"0001209191-22-005511","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919122005511/doc4.xml","form_type":"4"}},{"id":2422909,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-29T02:22:18.000Z","date":"2022-01-26","kind":"other","acquired":true,"shares":56244,"price":13.2,"value":742420.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":226704,"source":{"system":"sec-edgar","filing":"0001209191-22-005511","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919122005511/doc4.xml","form_type":"4"}},{"id":2422908,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-29T02:22:18.000Z","date":"2022-01-26","kind":"other","acquired":true,"shares":56244,"price":13.2,"value":742420.8,"ownership":{"direct":false,"nature":"See footnote (4),"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."}],"balance_after":226704,"source":{"system":"sec-edgar","filing":"0001209191-22-005511","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919122005511/doc4.xml","form_type":"4"}},{"id":2422907,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-29T02:22:18.000Z","date":"2022-01-26","kind":"other","acquired":true,"shares":374962,"price":13.2,"value":4949498.4,"ownership":{"direct":false,"nature":"See footnote (4),"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."}],"balance_after":1511362,"source":{"system":"sec-edgar","filing":"0001209191-22-005511","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919122005511/doc4.xml","form_type":"4"}},{"id":2576381,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-08T22:18:30.000Z","date":"2021-09-07","kind":"sale","acquired":false,"shares":26,"price":33.93,"value":882.18,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"These shares of the Issuer's common stock were sold in a block order at price of $33.93 pursuant to a Rule 10b5-1 trading plan established by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OPM. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":96190,"source":{"system":"sec-edgar","filing":"0000947871-21-000986","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000986/ownership.xml","form_type":"4"}},{"id":2576380,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-08T22:18:30.000Z","date":"2021-09-07","kind":"sale","acquired":false,"shares":861,"price":33.93,"value":29213.73,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"These shares of the Issuer's common stock were sold in a block order at price of $33.93 pursuant to a Rule 10b5-1 trading plan established by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI VII. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. OrbiMed Advisors and GP VII exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":3177041,"source":{"system":"sec-edgar","filing":"0000947871-21-000986","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000986/ownership.xml","form_type":"4"}},{"id":2576379,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-08T22:18:30.000Z","date":"2021-09-03","kind":"sale","acquired":false,"shares":212,"price":34,"value":7208.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares of the Issuer's common stock were sold in a block order at price of $34.00 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Partners Master Fund Limited (\"OPM\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OPM. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":96216,"source":{"system":"sec-edgar","filing":"0000947871-21-000986","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000986/ownership.xml","form_type":"4"}},{"id":2576378,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-08T22:18:30.000Z","date":"2021-09-03","kind":"sale","acquired":false,"shares":6985,"price":34,"value":237490.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were sold in a block order at price of $34.00 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments VII, LP (\"OPI VII\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI VII. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. OrbiMed Advisors and GP VII exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":3177902,"source":{"system":"sec-edgar","filing":"0000947871-21-000986","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000986/ownership.xml","form_type":"4"}},{"id":2582270,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-03T00:27:25.000Z","date":"2021-09-02","kind":"sale","acquired":false,"shares":483,"price":34.24,"value":16537.92,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F9","text":"These shares of the Issuer's common stock were sold in a block order at price of $34.24 pursuant to a Rule 10b5-1 trading plan established by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OPM. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":96428,"source":{"system":"sec-edgar","filing":"0000947871-21-000979","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000979/ownership.xml","form_type":"4"}},{"id":2582269,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-03T00:27:25.000Z","date":"2021-09-02","kind":"sale","acquired":false,"shares":15941,"price":34.24,"value":545819.84,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"These shares of the Issuer's common stock were sold in a block order at price of $34.24 pursuant to a Rule 10b5-1 trading plan established by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI VII. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. OrbiMed Advisors and GP VII exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":3184887,"source":{"system":"sec-edgar","filing":"0000947871-21-000979","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000979/ownership.xml","form_type":"4"}},{"id":2582268,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-03T00:27:25.000Z","date":"2021-09-01","kind":"sale","acquired":false,"shares":382,"price":33.98,"value":12980.36,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"These shares of the Issuer's common stock were sold in a block order at price of $33.98 pursuant to a Rule 10b5-1 trading plan established by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OPM. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":96911,"source":{"system":"sec-edgar","filing":"0000947871-21-000979","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000979/ownership.xml","form_type":"4"}},{"id":2582267,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-03T00:27:25.000Z","date":"2021-09-01","kind":"sale","acquired":false,"shares":12586,"price":33.98,"value":427672.28,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"These shares of the Issuer's common stock were sold in a block order at price of $33.98 pursuant to a Rule 10b5-1 trading plan established by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI VII. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. OrbiMed Advisors and GP VII exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":3200828,"source":{"system":"sec-edgar","filing":"0000947871-21-000979","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000979/ownership.xml","form_type":"4"}},{"id":2582266,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-03T00:27:25.000Z","date":"2021-08-31","kind":"sale","acquired":false,"shares":249,"price":33.94,"value":8451.06,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares of the Issuer's common stock were sold in a block order at price of $33.94 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Partners Master Fund Limited (\"OPM\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OPM. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":97293,"source":{"system":"sec-edgar","filing":"0000947871-21-000979","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000979/ownership.xml","form_type":"4"}},{"id":2582265,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-03T00:27:25.000Z","date":"2021-08-31","kind":"sale","acquired":false,"shares":8223,"price":33.94,"value":279088.62,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were sold in a block order at price of $33.94 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments VII, LP (\"OPI VII\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI VII. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. OrbiMed Advisors and GP VII exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":3213414,"source":{"system":"sec-edgar","filing":"0000947871-21-000979","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000979/ownership.xml","form_type":"4"}},{"id":2586961,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-30T22:37:01.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":197,"price":33.92,"value":6682.24,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F9","text":"These shares of the Issuer's common stock were sold in a block order at price of $33.92 pursuant to a Rule 10b5-1 trading plan established by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OPM. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":97542,"source":{"system":"sec-edgar","filing":"0000947871-21-000968","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000968/ownership.xml","form_type":"4"}},{"id":2586960,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-30T22:37:01.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":6500,"price":33.92,"value":220480.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"These shares of the Issuer's common stock were sold in a block order at price of $33.92 pursuant to a Rule 10b5-1 trading plan established by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI VII. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. OrbiMed Advisors and GP VII exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":3221637,"source":{"system":"sec-edgar","filing":"0000947871-21-000968","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000968/ownership.xml","form_type":"4"}},{"id":2586959,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-30T22:37:01.000Z","date":"2021-08-27","kind":"sale","acquired":false,"shares":209,"price":33.94,"value":7093.46,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"These shares of the Issuer's common stock were sold in a block order at price of $33.94 pursuant to a Rule 10b5-1 trading plan established by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OPM. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":97739,"source":{"system":"sec-edgar","filing":"0000947871-21-000968","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000968/ownership.xml","form_type":"4"}},{"id":2586958,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-30T22:37:01.000Z","date":"2021-08-27","kind":"sale","acquired":false,"shares":6884,"price":33.94,"value":233642.96,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"These shares of the Issuer's common stock were sold in a block order at price of $33.94 pursuant to a Rule 10b5-1 trading plan established by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI VII. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. OrbiMed Advisors and GP VII exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":3228137,"source":{"system":"sec-edgar","filing":"0000947871-21-000968","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000968/ownership.xml","form_type":"4"}},{"id":2586957,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-30T22:37:01.000Z","date":"2021-08-26","kind":"sale","acquired":false,"shares":126,"price":34.52,"value":4349.52,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares of the Issuer's common stock were sold in a block order at price of $34.52 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Partners Master Fund Limited (\"OPM\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OPM. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":97948,"source":{"system":"sec-edgar","filing":"0000947871-21-000968","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000968/ownership.xml","form_type":"4"}},{"id":2586956,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-30T22:37:01.000Z","date":"2021-08-26","kind":"sale","acquired":false,"shares":4157,"price":34.52,"value":143499.64,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were sold in a block order at price of $34.52 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments VII, LP (\"OPI VII\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI VII. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. OrbiMed Advisors and GP VII exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":3235021,"source":{"system":"sec-edgar","filing":"0000947871-21-000968","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000968/ownership.xml","form_type":"4"}},{"id":2591284,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-26T00:43:35.000Z","date":"2021-08-25","kind":"sale","acquired":false,"shares":208,"price":34.34,"value":7142.72,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F9","text":"These shares of the Issuer's common stock were sold in a block order at price of $34.34 pursuant to a Rule 10b5-1 trading plan established by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OPM. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":98074,"source":{"system":"sec-edgar","filing":"0000947871-21-000961","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000961/ownership.xml","form_type":"4"}},{"id":2591283,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-26T00:43:35.000Z","date":"2021-08-25","kind":"sale","acquired":false,"shares":6874,"price":34.34,"value":236053.16,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"These shares of the Issuer's common stock were sold in a block order at price of $34.34 pursuant to a Rule 10b5-1 trading plan established by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI VII. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. OrbiMed Advisors and GP VII exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":3239178,"source":{"system":"sec-edgar","filing":"0000947871-21-000961","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000961/ownership.xml","form_type":"4"}},{"id":2591282,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-26T00:43:35.000Z","date":"2021-08-24","kind":"sale","acquired":false,"shares":119,"price":34.07,"value":4054.33,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"These shares of the Issuer's common stock were sold in a block order at price of $34.07 pursuant to a Rule 10b5-1 trading plan established by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OPM. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":98282,"source":{"system":"sec-edgar","filing":"0000947871-21-000961","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000961/ownership.xml","form_type":"4"}},{"id":2591281,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-26T00:43:35.000Z","date":"2021-08-24","kind":"sale","acquired":false,"shares":3920,"price":34.07,"value":133554.4,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"These shares of the Issuer's common stock were sold in a block order at price of $34.07 pursuant to a Rule 10b5-1 trading plan established by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI VII. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. OrbiMed Advisors and GP VII exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":3246052,"source":{"system":"sec-edgar","filing":"0000947871-21-000961","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000961/ownership.xml","form_type":"4"}},{"id":2591280,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-26T00:43:35.000Z","date":"2021-08-23","kind":"sale","acquired":false,"shares":209,"price":34.06,"value":7118.54,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares of the Issuer's common stock were sold in a block order at price of $34.06 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Partners Master Fund Limited (\"OPM\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OPM. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":98401,"source":{"system":"sec-edgar","filing":"0000947871-21-000961","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000961/ownership.xml","form_type":"4"}},{"id":2591279,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-26T00:43:35.000Z","date":"2021-08-23","kind":"sale","acquired":false,"shares":6885,"price":34.06,"value":234503.1,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were sold in a block order at price of $34.06 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments VII, LP (\"OPI VII\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI VII. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. OrbiMed Advisors and GP VII exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":3249972,"source":{"system":"sec-edgar","filing":"0000947871-21-000961","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000961/ownership.xml","form_type":"4"}},{"id":2596505,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-20T00:55:10.000Z","date":"2021-08-18","kind":"sale","acquired":false,"shares":78,"price":33.99,"value":2651.22,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"These shares of the Issuer's common stock were sold in a block order at price of $33.99 pursuant to a Rule 10b5-1 trading plan established by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OPM. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":98610,"source":{"system":"sec-edgar","filing":"0000947871-21-000950","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000950/ownership.xml","form_type":"4"}},{"id":2596504,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-20T00:55:10.000Z","date":"2021-08-18","kind":"sale","acquired":false,"shares":2852,"price":33.99,"value":96939.48,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"These shares of the Issuer's common stock were sold in a block order at price of $33.99 pursuant to a Rule 10b5-1 trading plan established by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI VII. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. OrbiMed Advisors and GP VII exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":3256857,"source":{"system":"sec-edgar","filing":"0000947871-21-000950","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000950/ownership.xml","form_type":"4"}},{"id":2596503,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-20T00:55:10.000Z","date":"2021-08-17","kind":"sale","acquired":false,"shares":512,"price":34.12,"value":17469.44,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares of the Issuer's common stock were sold in a block order at price of $34.12 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Partners Master Fund Limited (\"OPM\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OPM. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":98688,"source":{"system":"sec-edgar","filing":"0000947871-21-000950","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000950/ownership.xml","form_type":"4"}},{"id":2596502,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-20T00:55:10.000Z","date":"2021-08-17","kind":"sale","acquired":false,"shares":16886,"price":34.12,"value":576150.32,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were sold in a block order at price of $34.12 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments VII, LP (\"OPI VII\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI VII. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. OrbiMed Advisors and GP VII exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":3259439,"source":{"system":"sec-edgar","filing":"0000947871-21-000950","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000950/ownership.xml","form_type":"4"}},{"id":2632377,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-16T20:27:52.000Z","date":"2021-07-16","kind":"purchase","acquired":true,"shares":1666666,"price":6,"value":9999996.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were purchased in the Company's underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Shares are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\"), a registered investment adviser under the Investment Advisers Act, acts as the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors LLC (\"OrbiMed Advisors\"). OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is filed by OrbiMed Advisors, GP VII, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons, or David Bonita, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1666666,"source":{"system":"sec-edgar","filing":"0000947871-21-000776","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000776/ownership.xml","form_type":"4"}},{"id":2846869,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2021-02-20T00:09:47.000Z","date":"2021-02-17","kind":"exercise","acquired":false,"shares":1158412,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 17, 2021, the Series D Preferred Stock automatically converted into Common Stock on a 5.3-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 17, 2021, the Series D Preferred Stock automatically converted into Common Stock on a 5.3-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 17, 2021, the Series D Preferred Stock automatically converted into Common Stock on a 5.3-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationship, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, OrbiMed Capital, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":218568},"source":{"system":"sec-edgar","filing":"0000899243-21-007451","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924321007451/doc4.xml","form_type":"4"}},{"id":2846868,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2021-02-20T00:09:47.000Z","date":"2021-02-17","kind":"exercise","acquired":false,"shares":1737619,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 17, 2021, the Series D Preferred Stock automatically converted into Common Stock on a 5.3-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 17, 2021, the Series D Preferred Stock automatically converted into Common Stock on a 5.3-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 17, 2021, the Series D Preferred Stock automatically converted into Common Stock on a 5.3-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor of OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, OrbiMed Capital, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":327852},"source":{"system":"sec-edgar","filing":"0000899243-21-007451","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924321007451/doc4.xml","form_type":"4"}},{"id":2846867,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2021-02-20T00:09:47.000Z","date":"2021-02-17","kind":"exercise","acquired":false,"shares":14480162,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 17, 2021, the Series D Preferred Stock automatically converted into Common Stock on a 5.3-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 17, 2021, the Series D Preferred Stock automatically converted into Common Stock on a 5.3-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 17, 2021, the Series D Preferred Stock automatically converted into Common Stock on a 5.3-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationship, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, OrbiMed Capital, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2732106},"source":{"system":"sec-edgar","filing":"0000899243-21-007451","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924321007451/doc4.xml","form_type":"4"}},{"id":2846866,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-20T00:09:47.000Z","date":"2021-02-17","kind":"purchase","acquired":true,"shares":555566,"price":18,"value":10000188.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor of OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, OrbiMed Capital, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":883418,"source":{"system":"sec-edgar","filing":"0000899243-21-007451","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924321007451/doc4.xml","form_type":"4"}},{"id":2846865,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-20T00:09:47.000Z","date":"2021-02-17","kind":"purchase","acquired":true,"shares":1111100,"price":18,"value":19999800.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationship, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, OrbiMed Capital, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3843206,"source":{"system":"sec-edgar","filing":"0000899243-21-007451","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924321007451/doc4.xml","form_type":"4"}},{"id":2846864,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-20T00:09:47.000Z","date":"2021-02-17","kind":"exercise","acquired":true,"shares":218568,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 17, 2021, the Series D Preferred Stock automatically converted into Common Stock on a 5.3-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationship, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, OrbiMed Capital, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":218568,"source":{"system":"sec-edgar","filing":"0000899243-21-007451","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924321007451/doc4.xml","form_type":"4"}},{"id":2846863,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-20T00:09:47.000Z","date":"2021-02-17","kind":"exercise","acquired":true,"shares":327852,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 17, 2021, the Series D Preferred Stock automatically converted into Common Stock on a 5.3-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor of OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, OrbiMed Capital, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":327852,"source":{"system":"sec-edgar","filing":"0000899243-21-007451","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924321007451/doc4.xml","form_type":"4"}},{"id":2846862,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-20T00:09:47.000Z","date":"2021-02-17","kind":"exercise","acquired":true,"shares":2732106,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 17, 2021, the Series D Preferred Stock automatically converted into Common Stock on a 5.3-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationship, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, OrbiMed Capital, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2732106,"source":{"system":"sec-edgar","filing":"0000899243-21-007451","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924321007451/doc4.xml","form_type":"4"}},{"id":2909854,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":3,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Non-Voting Common Stock","published_at":"2021-01-12T22:47:18.000Z","date":"2021-01-11","kind":"purchase","acquired":true,"shares":41700,"price":60,"value":2502000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were purchased in the Company's underwritten public offering. Each share of the Issuer's Non-Voting Common Stock is convertible into one share of the Issuer's Common Stock at any time at the option of the holder without consideration subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were purchased in the Company's underwritten public offering. Each share of the Issuer's Non-Voting Common Stock is convertible into one share of the Issuer's Common Stock at any time at the option of the holder without consideration subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were purchased in the Company's underwritten public offering. Each share of the Issuer's Non-Voting Common Stock is convertible into one share of the Issuer's Common Stock at any time at the option of the holder without consideration subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Shares are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of OrbiMed GP VI. OrbiMed GP VI and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VI and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is filed by OrbiMed Advisors, OrbiMed GP VI, and OrbiMed Capital LLC (\"OrbiMed Capital\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated David Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons, or David Bonita, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5596886,"derivative":{"underlying":"Common Stock","underlying_shares":41700},"source":{"system":"sec-edgar","filing":"0000947871-21-000054","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000054/ownership.xml","form_type":"4"}},{"id":2952135,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Series C Preferred Stock","published_at":"2020-12-09T21:24:43.000Z","date":"2020-12-07","kind":"exercise","acquired":false,"shares":24555,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.  Each share of the Series C Preferred Stock automatically converted into shares of Common Stock on a one to 1.003350008 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.  Each share of the Series C Preferred Stock automatically converted into shares of Common Stock on a one to 1.003350008 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.  Each share of the Series C Preferred Stock automatically converted into shares of Common Stock on a one to 1.003350008 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by OrbiMed Genesis Master Fund, L.P. (\"Genesis\")"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"OrbiMed Capital is a relying advisor to OrbiMed Advisors. OrbiMed Capital and OrbiMed Advisors exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VII, Genesis, and OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":24637},"source":{"system":"sec-edgar","filing":"0001140361-20-027879","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000114036120027879/form4.xml","form_type":"4"}},{"id":2952134,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Series B Preferred Stock","published_at":"2020-12-09T21:24:43.000Z","date":"2020-12-07","kind":"exercise","acquired":false,"shares":9461,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.  Each share of the Series C Preferred Stock automatically converted into shares of Common Stock on a one to 1.003350008 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.  Each share of the Series C Preferred Stock automatically converted into shares of Common Stock on a one to 1.003350008 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.  Each share of the Series C Preferred Stock automatically converted into shares of Common Stock on a one to 1.003350008 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by OrbiMed Genesis Master Fund, L.P. (\"Genesis\")"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"OrbiMed Capital is a relying advisor to OrbiMed Advisors. OrbiMed Capital and OrbiMed Advisors exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VII, Genesis, and OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9461},"source":{"system":"sec-edgar","filing":"0001140361-20-027879","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000114036120027879/form4.xml","form_type":"4"}},{"id":2952133,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Series A Preferred Stock","published_at":"2020-12-09T21:24:43.000Z","date":"2020-12-07","kind":"exercise","acquired":false,"shares":50501,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.  Each share of the Series C Preferred Stock automatically converted into shares of Common Stock on a one to 1.003350008 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.  Each share of the Series C Preferred Stock automatically converted into shares of Common Stock on a one to 1.003350008 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.  Each share of the Series C Preferred Stock automatically converted into shares of Common Stock on a one to 1.003350008 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by OrbiMed Genesis Master Fund, L.P. (\"Genesis\")"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"OrbiMed Capital is a relying advisor to OrbiMed Advisors. OrbiMed Capital and OrbiMed Advisors exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VII, Genesis, and OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":50501},"source":{"system":"sec-edgar","filing":"0001140361-20-027879","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000114036120027879/form4.xml","form_type":"4"}},{"id":2952132,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Series C Preferred Stock","published_at":"2020-12-09T21:24:43.000Z","date":"2020-12-07","kind":"exercise","acquired":false,"shares":118398,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.  Each share of the Series C Preferred Stock automatically converted into shares of Common Stock on a one to 1.003350008 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.  Each share of the Series C Preferred Stock automatically converted into shares of Common Stock on a one to 1.003350008 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.  Each share of the Series C Preferred Stock automatically converted into shares of Common Stock on a one to 1.003350008 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are owned directly by OrbiMed Private Investments VII, LP (\"OPI VII\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"OrbiMed Capital is a relying advisor to OrbiMed Advisors. OrbiMed Capital and OrbiMed Advisors exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VII, Genesis, and OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":118794},"source":{"system":"sec-edgar","filing":"0001140361-20-027879","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000114036120027879/form4.xml","form_type":"4"}},{"id":2952131,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Series B Preferred Stock","published_at":"2020-12-09T21:24:43.000Z","date":"2020-12-07","kind":"exercise","acquired":false,"shares":2651042,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.  Each share of the Series C Preferred Stock automatically converted into shares of Common Stock on a one to 1.003350008 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.  Each share of the Series C Preferred Stock automatically converted into shares of Common Stock on a one to 1.003350008 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.  Each share of the Series C Preferred Stock automatically converted into shares of Common Stock on a one to 1.003350008 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are owned directly by OrbiMed Private Investments VII, LP (\"OPI VII\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"OrbiMed Capital is a relying advisor to OrbiMed Advisors. OrbiMed Capital and OrbiMed Advisors exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VII, Genesis, and OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2651042},"source":{"system":"sec-edgar","filing":"0001140361-20-027879","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000114036120027879/form4.xml","form_type":"4"}},{"id":2952130,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Series A Preferred Stock","published_at":"2020-12-09T21:24:43.000Z","date":"2020-12-07","kind":"exercise","acquired":false,"shares":243494,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.  Each share of the Series C Preferred Stock automatically converted into shares of Common Stock on a one to 1.003350008 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.  Each share of the Series C Preferred Stock automatically converted into shares of Common Stock on a one to 1.003350008 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.  Each share of the Series C Preferred Stock automatically converted into shares of Common Stock on a one to 1.003350008 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are owned directly by OrbiMed Private Investments VII, LP (\"OPI VII\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"OrbiMed Capital is a relying advisor to OrbiMed Advisors. OrbiMed Capital and OrbiMed Advisors exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VII, Genesis, and OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":243494},"source":{"system":"sec-edgar","filing":"0001140361-20-027879","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000114036120027879/form4.xml","form_type":"4"}},{"id":2952129,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-12-09T21:24:43.000Z","date":"2020-12-07","kind":"exercise","acquired":true,"shares":24637,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.  Each share of the Series C Preferred Stock automatically converted into shares of Common Stock on a one to 1.003350008 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by OrbiMed Genesis Master Fund, L.P. (\"Genesis\")"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"OrbiMed Capital is a relying advisor to OrbiMed Advisors. OrbiMed Capital and OrbiMed Advisors exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VII, Genesis, and OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":84599,"source":{"system":"sec-edgar","filing":"0001140361-20-027879","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000114036120027879/form4.xml","form_type":"4"}}],"next_cursor":"2020-12-09T21:24:43.000000Z,2952129"}